RxDoctor Payments DataLook up a doctor →

Aaron Gopal, MD

Interventional Cardiology · Spartanburg, SCNPI 1124401609

Payments from drug & device makers

$34,048in general payments, 2019–2025

Across 586 payments — averaging $58.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$11K
  • Inari Medical, Inc.$7K
  • Stryker$2K
  • Philips North America LLC$2K
  • Abiomed$1K
  • Abbott$1K
  • plus $10K from 44 others

What the payments were for

  • Speaking & faculty fees$2,8008%
  • Grants$7,40022%
  • Travel & lodging$2,4877%
  • Food & beverage$21,11162%
  • Education$2511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,048 in reported general payments places this provider in the 75th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$241,452
Medicare patients
927
Services billed
2,810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban148$138,004
JardianceEmpagliflozin63$48,697
EntrestoSacubitril/Valsartan26$25,014
XareltoRivaroxaban25$19,857
BrilintaTicagrelor18$13,560
Metoprolol Succinate215$1,704
ClopidogrelClopidogrel Bisulfate108$1,676
Ranolazine ErRanolazine15$689
Losartan Potassium80$686
Torsemide54$679
Prasugrel Hcl11$677
Labetalol Hcl14$556
Pravastatin Sodium27$469
Spironolactone90$447
Atorvastatin Calcium33$305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$297$138,004148 claims
Boehringer IngelheimJardiance$83$48,69763 claims
NovartisEntresto$368$25,01426 claims
Johnson & JohnsonXarelto$298$19,85725 claims
AstraZenecaBrilinta$34$13,56018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →